Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients

Cardiology Journal

Volumn 20, Issue 2, 2013, Pages 170-177

  Postula, Marek ^a   Janicki, Piotr K ^b   Rosiak, Marek ^c   Przybylkowski, Adam ^a   Kaplon Cieslicka, Agnieszka ^c   Grygorowicz, Tomasz ^a   Trzepla, Ewa ^c   Filipiak, Krzysztof J ^c   Czlonkowski, Andrzej ^a   Opolski, Grzegorz ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c The Medical University of Warsaw   (Poland)

Author keywords

Aspirin; Diabetes; Platelet function testing; Platelet reactivity; Salicylic acid

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; SALICYLIC ACID; THROMBOXANE B2;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLAND; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SALICYLIC ACID; THROMBOXANE B2;

EID: 84885199081     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0030     Document Type: Article

References (29)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971; 231: 232-235.
2. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prosta-glandin H2 synthase. Nat Struct Biol, 1995; 2: 637-643.
3. DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin do-sing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 2007; 56: 3014-3019.
4. Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost, 2007; 5: 2197-2203.
5. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res, 2010; 126: e318-e322.
6. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res, 2004; 113: 101-113.
7. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation, 2007; 115: 3156-3164.
8. Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehy-drothromboxane B(2). Thromb Haemost, 2009; 102: 404-411.
9. Grove EL, Hvas AM, Johnsen HL et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy ndividuals and patients with coronary artery disease. Thromb Haemost, 2010; 103: 1245-1253.
10. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets, 2011; 22: 188-195.
11. Gouya G, Jilma B, Niel M, Eichelberger B, Wolzt M, Panzer S. Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: a double blind randomized placebo controlled trial. Platelets, 2009; 20: 171-176.
12. Frelinger AL, 3rd, Furman MI, Linden MD et al. Residual arachi-donic acid-induced platelet activation via an adenosine diphosp-hate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation, 2006; 113: 2888-2896.
13. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med, 2007; 357: 2482-2494.
14. Golanski J, Chlopicki S, Golanski R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit, 2005; 27: 484-490.
15. Postula M, Kaplon-Cieslicka A, Rosiak M et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost, 2011; 9: 2291-2301.
16. Krivosikova Z, Spustova V, Dzurik R. A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Findings Exper-imental Clin Pharmacol, 1996; 18: 527-532.
17. Angiolillo DJ. Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion Endocrinol, Diabetes, Obesity, 2007; 14: 124-131.
18. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardio-vasc Dis, 2009; 52: 141-152.
19. Tang M, Mukundan M, Yang J et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther, 2006; 319: 1467-1476.
20. Awidi A, Saleh A, Dweik M et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels, 2011; 26: 516-522.
21. Lepantalo A, Mikkelsson J, Resendiz JC et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in co-ronary artery disease patients. Thromb Haemost, 2006; 95: 253-259.
22. Pulcinelli FM, Biasucci LM, Riondino S et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J, 2009; 30: 1279-1286.
23. Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost, 2011; 105: 336-344.
24. Ahmed N, Meek J, Davies GJ. Plasma salicylate level and aspi-rin resistance in survivors of myocardial infarction. J Thromb Thrombolysis; 29: 416-420.
25. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet, 2006; 367: 606-617.
26. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodyna-mic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv, 2011; 4: 180-187.
27. Peace A, McCall M, Tedesco T et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thrombosis Haemostasis, 2010; 8: 2323-2325.
28. Maree AO, Curtin RJ, Dooley M et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol, 2005; 46: 1258-1263.
29. Bordeaux BC, Qayyum R, Yanek LR et al. Effect of obesity on plate-let reactivity and response to low-dose aspirin. Prev Cardiol, 2010; 13: 56-62.